Literature DB >> 11189684

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

P C Prorok1, G L Andriole, R S Bresalier, S S Buys, D Chia, E D Crawford, R Fogel, E P Gelmann, F Gilbert, M A Hasson, R B Hayes, C C Johnson, J S Mandel, A Oberman, B O'Brien, M M Oken, S Rafla, D Reding, W Rutt, J L Weissfeld, L Yokochi, J K Gohagan.   

Abstract

The objectives of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial are to determine in screenees ages 55-74 at entry whether screening with flexible sigmoidoscopy (60-cm sigmoidoscope) can reduce mortality from colorectal cancer, whether screening with chest X-ray can reduce mortality from lung cancer, whether screening men with digital rectal examination (DRE) plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer, and whether screening women with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer. Secondary objectives are to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; to assess incidence, stage, and survival of cancer cases; and to investigate biologic and/or prognostic characterizations of tumor tissue and biochemical products as intermediate endpoints. The design is a multicenter, two-armed, randomized trial with 37,000 females and 37,000 males in each of the two arms. In the intervention arm, the PSA and CA125 tests are performed at entry, then annually for 5 years. The DRE, TVU, and chest X-ray exams are performed at entry and then annually for 3 years. Sigmoidoscopy is performed at entry and then at the 5-year point. Participants in the control arm follow their usual medical care practices. Participants will be followed for at least 13 years from randomization to ascertain all cancers of the prostate, lung, colorectum, and ovary, as well as deaths from all causes. A pilot phase was undertaken to assess the randomization, screening, and data collection procedures of the trial and to estimate design parameters such as compliance and contamination levels. This paper describes eligibility, consent, and other design features of the trial, randomization and screening procedures, and an outline of the follow-up procedures. Sample-size calculations are reported, and a data analysis plan is presented.

Entities:  

Mesh:

Year:  2000        PMID: 11189684     DOI: 10.1016/s0197-2456(00)00098-2

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  406 in total

1.  Use of Big Data to Estimate Prevalence of Defective DNA Repair Variants in the US Population.

Authors:  Jennifer Pugh; Sikandar G Khan; Deborah Tamura; Alisa M Goldstein; Maria Teresa Landi; John J DiGiovanna; Kenneth H Kraemer
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Available carbohydrates, glycemic load, and pancreatic cancer: is there a link?

Authors:  Cari L Meinhold; Kevin W Dodd; Li Jiao; Andrew Flood; James M Shikany; Jeanine M Genkinger; Richard B Hayes; Rachael Z Stolzenberg-Solomon
Journal:  Am J Epidemiol       Date:  2010-05-07       Impact factor: 4.897

3.  Dietary factors and risk of chronic lymphocytic leukemia and small lymphocytic lymphoma: a pooled analysis of two prospective studies.

Authors:  Huei-Ting Tsai; Amanda J Cross; Barry I Graubard; Martin Oken; Arthur Schatzkin; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10       Impact factor: 4.254

4.  Pancreatic cancer risk: associations with meat-derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.

Authors:  Kristin E Anderson; Steven J Mongin; Rashmi Sinha; Rachael Stolzenberg-Solomon; Myron D Gross; Regina G Ziegler; Jerome E Mabie; Adam Risch; Sally S Kazin; Timothy R Church
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

5.  Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma.

Authors:  Ying Gao; Hormuzd Katki; Barry Graubard; Michael Pollak; Michael Martin; Yuzhen Tao; Robert E Schoen; Timothy Church; Richard B Hayes; Mark H Greene; Sonja I Berndt
Journal:  Int J Cancer       Date:  2011-11-02       Impact factor: 7.396

6.  Screening for colorectal cancer: decisions in general practice.

Authors:  Leonard Leibovici; Abigail Fraser; Sarah Hellmann
Journal:  Br J Gen Pract       Date:  2004-04       Impact factor: 5.386

7.  Can suicide in young men be prevented by improving access and delivery among primary care services?

Authors:  André Tylee; Paul Walters
Journal:  Br J Gen Pract       Date:  2004-04       Impact factor: 5.386

8.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

10.  Aspirin Use and Mortality in Two Contemporary US Cohorts.

Authors:  Wen-Yi Huang; Sarah E Daugherty; Meredith S Shiels; Mark P Purdue; Neal D Freedman; Christian C Abnet; Albert R Hollenbeck; Richard B Hayes; Debra T Silverman; Sonja I Berndt
Journal:  Epidemiology       Date:  2018-01       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.